China Pharma Holdings (CPHI) Operating Leases (2019 - 2026)

China Pharma Holdings' (CPHI) quarterly Operating Leases came in at $92294.0 in Q1 2026, down 17.26% on a QoQ basis from $111548.0 in Q4 2025.

China Pharma Holdings (CPHI) Operating Leases (2019 - 2026) Analysis & Trends

China Pharma Holdings (CPHI) has 8 years of Operating Leases data on file, last reported at $92294.0 in Q1 2026.

Quarterly Operating Leases changed N/A year-over-year to $92294.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92294.0 (changed N/A YoY) and the FY2025 annual result came in at $111548.0, up 183.67% from the prior year.
Operating Leases slipped to $92294.0 in Q1 2026, from $111548.0 in the prior quarter.
In the past five years, Operating Leases ranged from a high of $198583.0 in Q3 2025 to a low of $20008.0 in Q1 2024.
A 5-year average of $84695.0 and a median of $82959.0 in 2022 frame the typical range for Operating Leases.
Annual changes were most pronounced in 2022 — Operating Leases surged 307.55% — and 2023, when it sank 81.08%.
Tracing CPHI's Operating Leases over 5 years: stood at $40445.0 in 2022, then declined by 1.32% to $39910.0 in 2023, then decreased by 1.47% to $39323.0 in 2024, then jumped by 183.67% to $111548.0 in 2025, then slipped by 17.26% to $92294.0 in 2026.
The last three Operating Leases figures came in at $92294.0 (Q1 2026), $111548.0 (Q4 2025), and $198583.0 (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-
2	Teva Pharmaceutical Industries	43.07 Bn	39.42 Bn	2.15 Bn
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn
5	United Therapeutics	22.19 Bn	19.53 Bn	683.80 Mn
6	Viatris	18.68 Bn	17.79 Bn	1.46 Bn
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-
10	China Pharma Holdings	42.70 Mn	42.39 Mn	83,566.00

Download Data